China's National Joint Procurement Office Disqualifies Eugia Pharma and JSC "Farmak" Over Supply Failures – Four‑Year and Two‑Year Bans Imposed Under Centralized Drug Procurement Rules
Policy / Regulatory

China’s National Joint Procurement Office Disqualifies Eugia Pharma and JSC “Farmak” Over Supply Failures – Four‑Year and Two‑Year Bans Imposed Under Centralized Drug Procurement Rules

The National Joint Procurement Office for Drugs announced that two selected companies in China's national centralized drug procurement program have been disqualified and placed on the "violation list" after failing…

Novo Nordisk's NovoGlic Wins Expanded NMPA Approval – First Weekly Insulin Icodec/Semaglutide Combination Broadens Type 2 Diabetes Care in China
CompanyDrug

Novo Nordisk’s NovoGlic Wins Expanded NMPA Approval – First Weekly Insulin Icodec/Semaglutide Combination Broadens Type 2 Diabetes Care in China

NMPA Approves New Indication for J&J's Tecvayli in Relapsed or Refractory Multiple Myeloma – Bispecific BCMA/CD3 Antibody Moves to First Relapse After ≥1 Prior Line
CompanyDrug

NMPA Approves New Indication for J&J’s Tecvayli in Relapsed or Refractory Multiple Myeloma – Bispecific BCMA/CD3 Antibody Moves to First Relapse After ≥1 Prior Line

Takeda's Adcetris Approved by NMPA for First-Line CD30-Positive PTCL – China's First and Only Targeted Therapy in Combination With CHP for sALCL and Other CD30-Positive Peripheral T-Cell Lymphomas
CompanyDrug

Takeda’s Adcetris Approved by NMPA for First-Line CD30-Positive PTCL – China’s First and Only Targeted Therapy in Combination With CHP for sALCL and Other CD30-Positive Peripheral T-Cell Lymphomas

BMS Secures Conditional NMPA Approval for Zenbexus (Iberdomide) – World's First Oral CELMoD Agent Wins China Landmark in Relapsed Multiple Myeloma
CompanyDrug

BMS Secures Conditional NMPA Approval for Zenbexus (Iberdomide) – World’s First Oral CELMoD Agent Wins China Landmark in Relapsed Multiple Myeloma

FDA Approves Priovant's LISRAYA (Brepocitinib) for Adult Dermatomyositis – First Oral Targeted JAK1/TYK2 Therapy in the Indication
CompanyDrug

FDA Approves Priovant’s LISRAYA (Brepocitinib) for Adult Dermatomyositis – First Oral Targeted JAK1/TYK2 Therapy in the Indication

Alphamab Oncology Doses First Patient in Phase III Trial of JSKN033 – World's First High‑Concentration Subcutaneous HER2 ADC/PD‑L1 Fixed‑Dose Combination for Recurrent Cervical Cancer
CompanyDrug

Alphamab Oncology Doses First Patient in Phase III Trial of JSKN033 – World’s First High‑Concentration Subcutaneous HER2 ADC/PD‑L1 Fixed‑Dose Combination for Recurrent Cervical Cancer

Junshi Biosciences Converts Loqtorzi Urothelial Carcinoma Indication to Full Approval; Subcutaneous Toripalimab (JS001sc) NDA Accepted in First‑Line HER2‑Expressing Disease
CompanyDrug

Junshi Biosciences Converts Loqtorzi Urothelial Carcinoma Indication to Full Approval; Subcutaneous Toripalimab (JS001sc) NDA Accepted in First‑Line HER2‑Expressing Disease

Eli Lilly's Retatrutide Beats Ozempic Head‑to‑Head in Phase 3 TRANSCEND-T2D-2 – Greater A1C Reduction and Roughly Double the Weight Loss in Type 2 Diabetes
CompanyDrug

Eli Lilly’s Retatrutide Beats Ozempic Head‑to‑Head in Phase 3 TRANSCEND-T2D-2 – Greater A1C Reduction and Roughly Double the Weight Loss in Type 2 Diabetes

HutchMed's Sovleplenib Granted FDA Orphan Drug Designation for Primary Immune Thrombocytopenia – Selective Syk Inhibitor Broadens Global Regulatory Footprint
CompanyDrug

HutchMed’s Sovleplenib Granted FDA Orphan Drug Designation for Primary Immune Thrombocytopenia – Selective Syk Inhibitor Broadens Global Regulatory Footprint

GSK Q3 2026 Revenue Rises 5% to GBP 8.9 Billion as Specialty Medicines Surge 15%, Vaccines Stumble on Weak Shingrix China Demand

GSK Q3 2026 Revenue Rises 5% to GBP 8.9 Billion as Specialty Medicines Surge 15%, Vaccines Stumble on Weak Shingrix China Demand

GlaxoSmithKline Plc (GSK; NYSE: GSK) reported Q3 2026 revenues of GBP 8.89 billion (USD 11.91 billion), up 5% at constant exchange rates (CER), driven by double-digit growth in specialty medicines, while vaccines sales declined amid weaker demand for Shingrix in…

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

Dizal Pharmaceutical Reports First‑Ever Profit as AstraZeneca's USD 600 Million Sunvozertinib Deal Drives 714% Revenue Surge
Company

Dizal Pharmaceutical Reports First‑Ever Profit as AstraZeneca’s USD 600 Million Sunvozertinib Deal Drives 714% Revenue Surge

Betta Pharmaceuticals Acquires Global Rights to SS202 Ultra‑Long‑Acting Monthly Growth Hormone from Gensciences – Deal Valued at Up to RMB 50 Million Plus Royalties
CompanyDeals

Betta Pharmaceuticals Acquires Global Rights to SS202 Ultra‑Long‑Acting Monthly Growth Hormone from Gensciences – Deal Valued at Up to RMB 50 Million Plus Royalties

Hengrui Pharma Q3 2026 Revenue Jumps 20.55% and Non-Recurring Net Profit Nearly Doubles – Innovative Drugs Now Drive 65% of Drug Sales as Generics Shrink
Company

Hengrui Pharma Q3 2026 Revenue Jumps 20.55% and Non-Recurring Net Profit Nearly Doubles – Innovative Drugs Now Drive 65% of Drug Sales as Generics Shrink

Kelun Pharma's Sac-TMT Wins CDE Review Acceptance for Seventh Indication – First-Line Non-Squamous NSCLC Combo with MSD's KEYTRUDA
CompanyDrug

Kelun Pharma’s Sac-TMT Wins CDE Review Acceptance for Seventh Indication – First-Line Non-Squamous NSCLC Combo with MSD’s KEYTRUDA

Fosun Pharma Posts 9M 2026 Results – Revenue Rises 5.81% to RMB 30.5 Billion as Innovative Drug Growth Fuels Profits and R&D Spending Surges 31%
Company

Fosun Pharma Posts 9M 2026 Results – Revenue Rises 5.81% to RMB 30.5 Billion as Innovative Drug Growth Fuels Profits and R&D Spending Surges 31%

Where biopharma's biggest deals take shape!

Your front-row seat to the deals reshaping the pharmaceutical landscape — mergers and acquisitions, licensing agreements, venture investments, and strategic partnerships. We track every major transaction, from blockbuster M&As to early-stage funding rounds, breaking down what each deal means for the companies, the pipeline, and the market.
M&A and Licensing
Astellas Inks Exclusive Option and License Deal for Audax's DAX-044 – Up to USD 1.3 Billion to Back Tumor-Targeted IL-12 Immunotherapy
CompanyDeals

Astellas Inks Exclusive Option and License Deal for Audax’s DAX-044 – Up to USD 1.3 Billion to Back Tumor-Targeted IL-12 Immunotherapy

Astellas Pharma Inc. (TYO: 4503) and Audax Biosciences Pty Ltd jointly announced that the two parties have entered into an exclusive option and license agreement for DAX-044, Audax's lead oncology…

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031
CompanyDeals

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031

Zymeworks Inks Global License and Collaboration Agreement with Roche for ZW209 – Up to USD 813 Million Deal for Novel DLL3‑Targeting Trispecific T Cell Engager
CompanyDeals

Zymeworks Inks Global License and Collaboration Agreement with Roche for ZW209 – Up to USD 813 Million Deal for Novel DLL3‑Targeting Trispecific T Cell Engager

Gilead to Acquire Oral IL‑23R Inhibitor HCXT‑2001 from PepStar Therapeutics for USD 1.275 Billion Upfront – Deepening Inflammation Pipeline with Long‑Acting Macrocyclic Peptide
CompanyDeals

Gilead to Acquire Oral IL‑23R Inhibitor HCXT‑2001 from PepStar Therapeutics for USD 1.275 Billion Upfront – Deepening Inflammation Pipeline with Long‑Acting Macrocyclic Peptide

Yifan Pharmaceutical Signs Exclusive Commercialization Agreement With Eisai for Halaven in Mainland China – Originator Anti-Tumor Drug Strengthens Oncology Portfolio
CompanyDeals

Yifan Pharmaceutical Signs Exclusive Commercialization Agreement With Eisai for Halaven in Mainland China – Originator Anti-Tumor Drug Strengthens Oncology Portfolio

- Advertisement -
Baheal Pharmaceutical Completes ~USD 11 Million Investment in Zap Medical – Subsidiary Baheal Health Exercises Warrants for Series E‑1 Preferred Shares
CompanyDeals

Baheal Pharmaceutical Completes ~USD 11 Million Investment in Zap Medical – Subsidiary Baheal Health Exercises Warrants for Series E‑1 Preferred Shares

Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1
CompanyDeals

Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech's CNS and Brain‑Penetrant Drug Pipeline
CompanyDeals

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech’s CNS and Brain‑Penetrant Drug Pipeline

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances "Closed‑Loop Nerve Bundle Modulation" Platform
CompanyDeals

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances “Closed‑Loop Nerve Bundle Modulation” Platform

NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs
Policy / Regulatory

NMPA Proposes Drug Market Exclusivity Framework – Up to Seven Years for Rare Disease Therapies and Two Years for Pediatric Drugs

The Comprehensive Department of China's National Medical Products Administration (NMPA) has released the Measures for the Implementation of Drug Market Exclusivity (Draft for Comment), proposing a unified exclusivity regime that…

China's National Joint Procurement Office Opens Information Change Channel for National VBP Selected Products – MAH Changes, Entrusted Manufacturer Adjustments and Supplementary Selection Now Permitted While Retaining Selected Status
Policy / Regulatory

New VBP Announcement Opens MAH Change and Supplementary Selection Channel – Paper Applications Due Before 30 October 2026 in Shanghai

US Treasury Proposes Extending Outbound Investment Controls to Biotechnology Under the COINS Act – Chinese Pharma Access to US Capital Faces Tighter Restrictions
Policy / Regulatory

US Treasury Proposes Extending Outbound Investment Controls to Biotechnology Under the COINS Act – Chinese Pharma Access to US Capital Faces Tighter Restrictions

NMPA Publishes 110th Batch of Chemical Generic Drug Reference Listed Drug Catalog – 28 New Specifications Added
Policy / Regulatory

NMPA Publishes 110th Batch of Chemical Generic Drug Reference Listed Drug Catalog – 28 New Specifications Added

More News

Joincare's LZSN2501 Cleared for Phase I Clinical Trials by NMPA – Dual-Epitope Bispecific Anti-FXI Antibody Targets VTE Prevention After Total Knee Arthroplasty
CompanyDrug

Joincare’s LZSN2501 Cleared for Phase I Clinical Trials by NMPA – Dual-Epitope Bispecific Anti-FXI Antibody Targets VTE Prevention After Total Knee Arthroplasty

Hengrui's Remimazolam Tosylate Wins China Approval for ICU Sedation During Mechanical Ventilation – Ruibeining Expands Into Critical Care
CompanyDrug

Hengrui’s Remimazolam Tosylate Wins China Approval for ICU Sedation During Mechanical Ventilation – Ruibeining Expands Into Critical Care

Enhertu Wins EU Approval in Resected HER2-Positive Breast Cancer – Daiichi Sankyo's ADC Cuts Recurrence Risk by 53% Versus T-DM1
CompanyDrug

Enhertu Wins EU Approval in Resected HER2-Positive Breast Cancer – Daiichi Sankyo’s ADC Cuts Recurrence Risk by 53% Versus T-DM1

Livzon Pharma's LZSN2501 Wins NMPA Clinical Trial Approval for VTE Prevention After Knee Arthroplasty – Bi-Epitopic Bispecific Anti-FXI Antibody Targets Next-Generation Anticoagulation
CompanyDrug

Livzon Pharma’s LZSN2501 Wins NMPA Clinical Trial Approval for VTE Prevention After Knee Arthroplasty – Bi-Epitopic Bispecific Anti-FXI Antibody Targets Next-Generation Anticoagulation

Innovent's Sintilimab Plus Nogileucel (GC101) Melanoma NDA Accepted by NMPA – Backed by 57% Progression Risk Reduction in MIZAR-003
Others

Innovent’s Sintilimab Plus Nogileucel (GC101) Melanoma NDA Accepted by NMPA – Backed by 57% Progression Risk Reduction in MIZAR-003

WuXi AppTec Q3 Revenue Jumps 38% as Backlog Hits RMB 76.74 Billion – Full-Year Guidance Raised
Company

WuXi AppTec Q3 Revenue Jumps 38% as Backlog Hits RMB 76.74 Billion – Full-Year Guidance Raised

HutchMed's SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC
CompanyDrug

HutchMed’s SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC

Astellas' Non-Hormonal VEOZA Gains NMPA NDA Acceptance for Menopausal Hot Flashes in China
CompanyDrug

Astellas’ Non-Hormonal VEOZA Gains NMPA NDA Acceptance for Menopausal Hot Flashes in China

Show More